Fusion Pharmaceuticals FUSN signed a definitive agreement with AstraZeneca AZN. Per the agreement terms, the pharma giant will acquire all outstanding shares of Fusion for $21 per share in cash, aggregating to $2.0 billion.
https://www.nasdaq.com/articles/fusion-fusn-up-99-on-$2.4b-buyout-offer-from-astrazeneca